Saad Usmani, MD, MBBS, MBA, Levine Cancer Institute and Atrium Health, Charlotte, NC, gives an update on the CARTITUDE-1 (NCT03548207) Phase 1b/2 study at 18 months of follow-up. In this trial, ciltacabtagene autoleucel (cilta-cel) was given to patients with relapsed/refractory (R/R) multiple myeloma. Dr Usmani reports an overall response rate among 97 patients of 98% with a stringent complete response (CR) of 80.4%. The median duration of response was 24 months, and has not been reached in patients who achieved stringent CR. The 18-month progression-free survival rate was 66% and the 18-month overall survival was 81%. Dr Usmani comments on the safety profile of cilta-cel, highlighting the benefits of bridging therapy, and outlines other trials investigating the safety and efficacy of cilta-cel in patients with myeloma. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.